Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardio Diagnostics HoldingsCDIO -6.94%53 Cash-to-Debt is 15.10 as of Jun. 2026, which is 87% above its 10-year median of 8.07. GuruFocus rates CDIO with a GF Score™ of 53/100 and a GF Value™ of $1.80 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 1,400 Biotechnology companies, Cardio Diagnostics Holdings ranks better than 57.86% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cardio Diagnostics Holdings's cash to debt ratio for the quarter that ended in Jun. 2026 was 15.10.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cardio Diagnostics Holdingscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Cardio Diagnostics Holdings's Cash-to-Debt or its related term are showing as below:
CDIO'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.02 Med: 8.07 Max: No Debt
Current: 15.1
During the past 6 years, Cardio Diagnostics Holdings's highest Cash to Debt Ratio was No Debt. The lowest was 1.02. And the median was 8.07.
CDIO's Cash-to-Debt is ranked better than 57.86% of 1400
companies
in the Biotechnology industry
Industry Median: 6.315
vs CDIO: 15.10
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Cardio Diagnostics Holdings Cash-to-Debt Related Terms
Cardio Diagnostics Holdings Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Cardio Diagnostics Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardio Diagnostics Holdings Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Cardio Diagnostics Holdings's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardio Diagnostics Holdings (CDIO) has a Cash-to-Debt of 15.10 as of Jun. 2026. This is 87% above median its historical median of 8.07. Over the past decade, Cardio Diagnostics Holdings' Cash-to-Debt has ranged from 1.02 to 10,000.00. According to the industry distribution chart, Cardio Diagnostics Holdings ranks #590 out of 1400 companies in the Biotechnology industry, placing it in the top 42.1%.
Is Cardio Diagnostics Holdings' Cash-to-Debt too high?
Cardio Diagnostics Holdings' current Cash-to-Debt of 15.10 is 87% above median its 10-year median of 8.07. Over the past 10 years, this metric has ranged from a low of 1.02 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.32. Cardio Diagnostics Holdings' value of 15.10 is 139.1% above this industry median. Based on the distribution chart, Cardio Diagnostics Holdings ranks #590 out of 1400 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cardio Diagnostics Holdings has a GF Score™ of 53/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cardio Diagnostics Holdings' Cash-to-Debt compare to ERNA and LABT?
According to the Biotechnology industry distribution chart, Cardio Diagnostics Holdings ranks #590 out of 1400 companies for Cash-to-Debt. This puts Cardio Diagnostics Holdings in the upper half of its industry. The industry median Cash-to-Debt is 6.32. Cardio Diagnostics Holdings' value of 15.10 is 139.1% above this benchmark. Historically, Cardio Diagnostics Holdings' own Cash-to-Debt has ranged from 1.02 to 10,000.00 over the past decade. While the company's 10-year median is 8.07 vs. the industry median of 6.32, Cardio Diagnostics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.32, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardio Diagnostics Holdings's current Cash-to-Debt of 15.10 is 139.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardio Diagnostics Holdings's current Cash-to-Debt is 15.10, which is 87% above median its own 10-year median of 8.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardio Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings (CDIO) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.80, compared to a current price of $2.02 — trading 12.4% above its estimated fair value. The current Cash-to-Debt is 15.10, which is 87% above median its 10-year median of 8.07 and 139.1% above the Biotechnology industry median of 6.32. Cardio Diagnostics Holdings' overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Cardio Diagnostics Holdings (CDIO), the current Cash-to-Debt is 15.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardio Diagnostics Holdings (CDIO) Overvalued in 2026?
Based on GuruFocus' analysis, Cardio Diagnostics Holdings stock appears to be overvalued.
The current stock price of $2.02 is trading 12.4% above its estimated GF Value™ of $1.80.
GuruFocus considers Cardio Diagnostics Holdings to be Modestly Overvalued.
Key valuation signals for CDIO:
Cash-to-Debt: 15.10 (87% above median its 10-year median of 8.07)
GF Value™: $1.80 vs. price of $2.02 (12.4% above fair value)
Industry Position: 139.1% above the Biotechnology median (#590 of 1400)
No single metric tells the full story. See the CDIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
53GF Score
Get the complete analysis for CDIO
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CDIO has been successfully added to your 
